Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Blueprint Medicines
Pharmaceutical Preparation ManufacturingUnited StatesNASDAQ: BPMC
Last verified 12 days agoblueprintmedicines.com
Blueprint Medicines Corporation, headquartered in the United States, is a leading player in the pharmaceutical preparation manufacturing industry. Founded in 2008, the company has made significant strides in developing targeted therapies for genomically defined cancers, rare diseases, and cancer immunotherapy.
With a focus on precision medicine, Blueprint Medicines offers a unique portfolio of innovative products, including targeted therapies that address specific genetic mutations. Their commitment to advancing treatment options has positioned them as a key competitor in the oncology market.
Notable achievements include the successful launch of several breakthrough therapies, which have garnered attention for their efficacy and safety profiles. As a pioneer in the field, Blueprint Medicines continues to push the boundaries of science, striving to improve patient outcomes and redefine treatment paradigms.
68
DitchCarbon score
+26 vs industry average
Blueprint Medicines’s score of 68 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Blueprint Medicines?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
20202021202220232024202520262027
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Blueprint Medicines's reported carbon emissions
Blueprint Medicines, a US-headquartered pharmaceutical preparation manufacturing company, reported its 2024 carbon emissions. The company's total Scope 1 and 2 market-based emissions were approximately 1,028,020 kg CO2e, comprising around 208,180 kg CO2e from Scope 1 and approximately 819,840 kg CO2e from Scope 2. Location-based Scope 1 and 2 emissions for the same period were approximately 1,023,220 kg CO2e. As a subsidiary of Sanofi, Blueprint Medicines Corporation's SBTi targets are cascaded from Sanofi.
Assessing Blueprint Medicines as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Blueprint Medicines and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Blueprint Medicines’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Blueprint Medicines yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from SanofiSee details
Active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
Inherited from SanofiSee details
Not active
RE 100
Inherited from SanofiSee details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Blueprint Medicines12 days ago
68
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more